Literature DB >> 11874489

Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome.

Julia J Scarisbrick1, Alison J Woolford, Eduardo Calonje, Andrew Photiou, Sylvia Ferreira, Guy Orchard, Robin Russell-Jones, Sean J Whittaker.   

Abstract

There are few data on the molecular pathogenesis of cutaneous T cell lymphomas. A recent allelotyping study by our group identified frequent allelic loss on 9p, 10q, and 17p including losses on 9p21 in 16% of patients with mycosis fungoides and 46% with Sezary syndrome. The P15 and P16 genes are intricately linked on 9p21 and can be inactivated in melanoma and non-Hodgkin's lymphoma. We have therefore studied 76 patients with either mycosis fungoides or Sezary syndrome for abnormalities of these genes. DNA samples were analyzed for loss of heterozygosity, homozygous deletion, intragenic mutations, and promoter methylation. In addition P15 and P16 protein expression was assessed. Microsatellite analysis was informative in 73 of 76 cases: allelic loss on 9p21 was identified in 18 patients (25%), including 12 of 57 with mycosis fungoides (21%) and six of 16 with Sezary syndrome (37%). Single strand conformation polymorphism analysis of the entire coding regions of both genes did not identify any mutations, although two polymorphisms were identified including C613A, which has not previously been described. P15 and P16 gene promoter methylation was found in 45% and 29% of patients, respectively. Furthermore aberrant P15 protein expression was detected in 85% of patients analyzed with P15 gene abnormalities and abnormal P16 expression in 59% with P16 gene abnormalities. These abnormalities were not dependent on cutaneous stage of disease. This study suggests that abnormalities of the P15 and P16 genes are common in both early and advanced stages of mycosis fungoides and Sezary syndrome and that these genes may be inactivated by allelic loss and aberrant promoter methylation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11874489     DOI: 10.1046/j.0022-202x.2001.01682.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  17 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 2.  Sézary Syndrome: Clinical and Biological Aspects.

Authors:  Rebecca Kohnken; Stephanie Fabbro; Justin Hastings; Pierluigi Porcu; Anjali Mishra
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

3.  High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.

Authors:  Michael K Kiessling; Patrick A Oberholzer; Chandrani Mondal; Maria B Karpova; Marie C Zipser; William M Lin; Michael Girardi; Laura E Macconaill; Sarah M Kehoe; Charlie Hatton; Lars E French; Levi A Garraway; Gernot Polier; Dorothee Süss; Claus-Detlev Klemke; Peter H Krammer; Karsten Gülow; Reinhard Dummer
Journal:  Blood       Date:  2011-01-05       Impact factor: 22.113

Review 4.  Methotrexate and Pralatrexate.

Authors:  Gary S Wood; Jianqiang Wu
Journal:  Dermatol Clin       Date:  2015-08-01       Impact factor: 3.478

5.  Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death.

Authors:  Paula V Cabrera; Maho Amano; Junya Mitoma; Jessica Chan; Jonathan Said; Minoru Fukuda; Linda G Baum
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

Review 6.  Cutaneous T-cell lymphoma: Biologic targets for therapy.

Authors:  Jaehyuk Choi; Francine Foss
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

7.  Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.

Authors:  Clara Curiel-Lewandrowski; Hisato Yamasaki; Chuan Ping Si; Xiaoyi Jin; Yujun Zhang; Jillian Richmond; Marina Tuzova; Kevin Wilson; Beth Sullivan; David Jones; Nataliya Ryzhenko; Frederick Little; Thomas S Kupper; David M Center; William W Cruikshank
Journal:  J Clin Invest       Date:  2011-11-14       Impact factor: 14.808

8.  STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes.

Authors:  Qian Zhang; Hong Y Wang; Anders Woetmann; Puthiyaveettil N Raghunath; Niels Odum; Mariusz A Wasik
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

Review 9.  Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

10.  Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.

Authors:  Jasmine Zain; Owen A O'Connor
Journal:  Invest New Drugs       Date:  2010-12-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.